Southern Research Institute Licenses Drug Compound to Virium

The Southern Research Institute, a network of collaborative centers for scientific discovery and technology development, reported it has licensed the rights to its anticancer compound 4’-Thio-Ara-C to Virium Pharmaceuticals.

According to the institute, six of its anticancer drugs have received FDA approval and are on the market. Six others, including 4’-Thio-Ara-C, are in late stage preclinical testing or in early clinical trials.

The 4’-Thio-Ara-C compound, now registered to Virium as VP700, has shown activity against certain types of leukemia and autoimmune diseases. It is a third generation, novel nucleoside analog that has completed two Phase I trials, the group added.